Type II Mode of JAK2 Inhibition and Destabilization Are Potential Therapeutic Approaches Against the Ruxolitinib Resistance Driven Myeloproliferative Neoplasms
Frontiers in Oncology(2024)
Key words
myeloproliferative neoplasm,JAK2-V617F,ruxolitinib resistance,Hsp90 inhibitior,type I JAK2 inhibition
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined